A review of the long-term protection after hepatitis A and B vaccination
Introduction
Viral hepatitis is still a cause of considerable morbidity and mortality in the world. On worldwide basis, approximately 1.4 million cases of hepatitis A are reported every year. The true incidence, however, has been estimated to be 3–10 times higher.
Regarding hepatitis B, more than a third of the world's population has been infected. The World Health Organization has estimated (2000) that there are 367 million chronic carriers of hepatitis B worldwide, and approximately 1 million deaths per year as a consequence of chronic complications and acute fulminant disease.
Hepatitis B vaccines have been licensed since 1982, the recombinant ones since 1986, hepatitis A vaccine since 1992. In 1996, a combined hepatitis A and B vaccine became available. An update on the long-term protection conferred by hepatitis A and hepatitis B vaccines is given in the following paragraphs.
Section snippets
Hepatitis B vaccine and long-term protection
Hepatitis B vaccines have been shown safe and very effective in protecting against hepatitis B. Early data from the Taiwan vaccination programme (started in 1984) showed good efficacy in reducing chronic HBV infection, decrease in hepatocellular carcinoma and fulminant hepatitis in Children.1
The primary course of a hepatitis B vaccination can consist of three or four doses, administered according to a 0, 1 and 6 months schedule or a 0, 1, 2 and 12 months schedule. A booster dose of vaccine,
Hepatitis A vaccine and long-term protection
Several inactivated and live attenuated vaccines against hepatitis A were developed in the 1980s and licensed for use in the early 1990s. These vaccines are safe and well-tolerated, they are highly immunogenic, and they provide long-lasting protection against hepatitis A disease in children and adults.18 High anti-HAV antibody levels and seroconversion rates have been observed in long-term follow-up studies in adults following the administration of a primary vaccination course (0–6, 0–12, or
Combined hepatitis A and B vaccine
Available data shows that the immunogenicity of a combined hepatitis A and B vaccine (Twinrix), administered according to the regular 0, 1, and 6 months schedule, is comparable to that of the monovalent vaccines.33, 34, 35, 36, 37 The decline in anti-HAV and anti-HBs antibody titers after combined hepatitis A and B vaccination is similar to that observed with monovalent vaccines, suggesting that this combined vaccine also provides long-term protection, as is the case for the monovalent
Frequently asked questions
In the final part of this manuscript the authors would like to answer, based on the above-mentioned evidence, some frequently asked questions related to booster administration, serology and schedules.
If a young child received a two-dose schedule of children's hepatitis A monodose vaccine, is a hepatitis A booster recommended or needed to guarantee long-term protection?
Let us summarise that the hepatitis A consensus statement holds also for infants and children, and is valid for all hepatitis A
Conclusion
Immunocompetent vaccinees, in particular travellers, can be reassured that following the correct administration (intramuscularly, in the Deltoid muscle) of a complete primary course of hepatitis A or hepatitis B vaccines (monovalent or combined), they will be afforded a long-term protection without requiring booster doses. Currently available data do not support the need for a booster vaccination.
By abandoning the administration of hepatitis A and hepatitis B booster doses among immunocompetent
References (44)
- et al.
Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan
J Pediatr
(2001) - et al.
Persistence of specific antibodies after hepatitis B vaccination
J Hepatol
(1988) - et al.
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination
Vaccine
(1996) - et al.
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study
Lancet
(2005) - et al.
18 year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children
Clin Gastroenterol Hepatol
(2004) - et al.
Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres
Vaccine
(2002) - et al.
Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants
Vaccine
(2005) - et al.
Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults
Vaccine
(2003) - et al.
Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees
Vaccine
(1992) Immunologic approaches to assessing the response to inactivated hepatitis A vaccine
J Hepatol
(1993)
Consensus Statement: hepatitis A booster vaccination: is there a need?
Lancet
The first combined vaccine against hepatitis A and B: an overview
Vaccine
A prospective, randomized, comparative US trial of a combined hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix) in adults
Vaccine
Long-term follow-up of hepatitis A vaccination in children
Vaccine
Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years
Vaccine
Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine
Vaccine
Hepatitis B vaccine—do we need boosters?
J Viral Hepatitis
Assessment of long-term efficacy of hepatitis B vaccine
Eur J Epidemiol
Ten-year serological follow-up of hepatitis B vaccine recipients
Indian J Gastroenterol
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory
Vaccine
Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan
J Inf Dis
Cited by (115)
Lamivudine use in pregnant HBsAg-females effectively reduces maternal viremia
2019, Arab Journal of Gastroenterology